Arthneeti
All Q4 FY26 results →
AA

Alkyl Amines Chemicals Ltd

Q4 FY26Chemicals & Petrochemicals

Alkyl Amines Chemicals Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹2,053
Market cap₹9.9K Cr
P/E44.1
Updated23 Aug 2026
Read4 min read

What the Q4 FY26 call signalled

2 of 4 strong

RevenueSlow growth
MarginMargins slightly up
CapexCapex planned
FundraiseNo fundraise planned

The short version

The company expects volume growth of about 5% to 10% annually, aligned with overall country growth (Page 9). The company expects a cautious optimism for future growth, with better times ahead after recent challenges.

From Alkyl Amines Chemicals Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Slow growth
  • The company expects volume growth of about 5% to 10% annually, aligned with overall country growth (Page 9).
  • FY26 volume was essentially flat, with minor fluctuations (±1%) (Page 7).
  • The company anticipates normal growth rates around 5-10% going forward, assuming market conditions stabilize (Pages 6-7).
  • Capacity utilization across plants is currently between 60% to 85%, with sufficient capacity for the next few years without major new investments (Page 12).
  • Ethylamines have sufficient capacity for the next 4-5 years; methylamines currently face some overcapacity (Page 10).

2 more points from Alkyl Amines Chemicals Ltd's call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

See what Alkyl Amines Chemicals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Current capex includes completion of an ongoing new product plant at Dahej and some engineering projects, estimated around INR 80 to 90 crores for FY27 and FY28.
  • No major new projects or product plants are planned immediately beyond the existing ones.
  • Maintenance capex is ongoing in the range of INR 20 to 30 crores annually.
  • Potential capex may arise if some R&D products currently in the pipeline progress to commercialization, but this is dependent on market stability and final investment decisions.

2 more points from Alkyl Amines Chemicals Ltd's call on capex

Pro opens every point from 15K+ earnings calls

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

Guidance-ranked
1Shiv Texchem
Rev 1Mar 2
2Yasho Industries Ltd
Rev 1Mar 3
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Alkyl Amines Chemicals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

- Customers often approach Alkyl Amines Chemicals Limited requesting specific products with required quantities and timelines (e.g., year 2 or 3). - The company gets early product demand indications directly from customers before product commercialization. - Typically, out of a dozen such product requests, only 1 or 2 products progress successfully to commercialization. - Official announcements to investors about new products are made only once the products are in the market. This suggests that while there are multiple pending product inquiries/orders at various stages, only a small fraction of these translate into confirmed commercial orders in the near term.

Alkyl Amines Chemicals Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹387 Cr, net profit ₹45 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Alkyl Amines's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

  • Indian Phosphate (Q4 FY26)

    H2 FY26 Revenue (Consolidated):** ₹580.25 Cr, up from ₹451.59 Cr in H2 FY25 — a year-on-year increase of ₹128.66 Cr. Key investor presentation takeaways from In

  • Vishnu Chemicals Ltd (Q4 FY26)

    Q4 FY26 Operating Revenues: ₹450.3 crore, up 14.7% YoY from ₹392.6 crore in Q4 FY25 (Page 5). Key investor presentation takeaways from Vishnu Chemicals Ltd's Q4

  • Rajputana Bio. (Q4 FY26)

    Revenue from Operations: ₹6,267.05 lakhs vs. Key investor presentation takeaways from Rajputana Bio.'s Q4 FY26 investor presentation — and how it ranks against

  • Neochem Bio (Q4 FY26)

    Capacity utilization improved from ~35% in FY24 to 53% in FY26, with significant headroom (47%) for growth without major capex. Key concall takeaways from…

Compare:vs Solar Industriesvs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Alkyl Amines Chemicals Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Alkyl Amines Chemicals Ltd Q4 FY26 results?

The company expects volume growth of about 5% to 10% annually, aligned with overall country growth (Page 9). The company expects a cautious optimism for future growth, with better times ahead after recent challenges.

What is Alkyl Amines Chemicals Ltd share price analysis?

Alkyl Amines Chemicals Ltd currently shows a neutral. The stock trades at a P/E of 44.1 with a market cap of ₹9,921 Cr. Investors should review the full earnings analysis for detailed insights.

Is Alkyl Amines Chemicals Ltd planning capital expenditure?

Current capex includes completion of an ongoing new product plant at Dahej and some engineering projects, estimated around INR 80 to 90 crores for FY27 and FY28.

Keep Alkyl Amines Chemicals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.